Confo's first drug candidate moves into clinical development Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that
Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company's clinical development program including